June continued a downturn in generic drug application submissions to the US Food and Drug Administration, which could be a potential concern about industry activity or simply the traditionally cyclical industry behavior.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?